🔗 Share this article World Health Organization Sounds Concern Over Severe Lack of Weight-Loss Injections Less than 10% of patients who could benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it releases its inaugural advice on the medications. With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just access to these injectable treatments. Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken. "Our new guidelines recognises that excess weight is a lifelong illness that can be treated with holistic and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and distribution challenges are significant hurdles to universal access to the jabs that can help people shift significant weight, says the agency. Weight-Loss Drug Supply Crisis Even under the present best projected case, the supply of these medications could only cover about 100 million people – under 10% of eligible patients, according to the WHO. The guideline urges nations and manufacturers to increase access, by measures such as licensing agreements. The intellectual property rights on a key compound – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026. How Obesity Drugs Work These medications imitate a natural hormone to slow digestion, curb appetite and enhance satiety so people eat less. People usually see weight reduction in the initial weeks of beginning the weekly injections. Evidence suggests users may see weight return after a year of discontinuing the treatment, when their typical appetite come back. To be above a healthy weight increases your likelihood for experiencing health problems, such as type 2 diabetes, heart disease, stroke, and some malignancies. Obesity concerns people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.
Less than 10% of patients who could benefit from weight-loss injections like Wegovy are able to get them, caution the World Health Organization as it releases its inaugural advice on the medications. With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is calling for increased and just access to these injectable treatments. Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken. "Our new guidelines recognises that excess weight is a lifelong illness that can be treated with holistic and ongoing treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus. High costs, constrained manufacturing, and distribution challenges are significant hurdles to universal access to the jabs that can help people shift significant weight, says the agency. Weight-Loss Drug Supply Crisis Even under the present best projected case, the supply of these medications could only cover about 100 million people – under 10% of eligible patients, according to the WHO. The guideline urges nations and manufacturers to increase access, by measures such as licensing agreements. The intellectual property rights on a key compound – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in several countries in 2026. How Obesity Drugs Work These medications imitate a natural hormone to slow digestion, curb appetite and enhance satiety so people eat less. People usually see weight reduction in the initial weeks of beginning the weekly injections. Evidence suggests users may see weight return after a year of discontinuing the treatment, when their typical appetite come back. To be above a healthy weight increases your likelihood for experiencing health problems, such as type 2 diabetes, heart disease, stroke, and some malignancies. Obesity concerns people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the WHO.